Investment of US$200m to help clients modernise R&D and accelerate new products to market through the combination of cloud computing, mobility and analytics
Global management consulting, technology services and outsourcing company Accenture has launched Accenture Accelerated R&D Services, a business service focused on delivering streamlined and integrated research and development functions that will help pharmaceutical companies bring new medications to patients using a more collaborative and efficient approach.
Accenture is investing more than US$200m to deliver this fully integrated, technology-enabled global business service that will drive more efficient and effective development of pharmaceutical products for clients.
Accelerated R&D Services helps life sciences companies bring drugs to market faster, at less cost and with reduced execution risks using a pay-for-performance business model for business process outsourcing. It.will leverage capabilities of the cloud, mobility and analytics to deliver integrated functions across clinical development, regulatory submissions, pharmacovigilance and market launch predicated on delivering better patient outcomes.
The business service encompasses:
‘An industry demand exists for new benchmarks that are driven by increasingly stringent health authority requirements, unsustainable fixed-cost models and the complexity of managing numerous vendor partners and technology systems,’ said David Boath, senior managing director, Life Sciences Accelerated R&D Services, Accenture.
‘With R&D Accelerated Services, we offer an improved and advanced type of service focused on efficiency, effectiveness and modern processes leveraging digital, the cloud and end-to-end solutions that draw on the management consulting, technology and outsourcing skills of our people.’